NCT07161544View on ClinicalTrials.gov

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

July 31, 2032

Study Completion Date

July 31, 2032

Conditions
Stargardt Disease
Interventions
BIOLOGICAL

AAVB-039

Single subretinal administration

Trial Locations (2)

75231

Retina Foundation of the Southwest, Dallas

77401

Retina Consultants of Texas, Bellaire

Sponsors

Collaborators (1)

AAVantgarde Bio UK Ltd
All Listed Sponsors
collaborator

AAVantgarde Bio UK Ltd

UNKNOWN

lead

AAVantgarde Bio Srl

INDUSTRY

NCT07161544 - A Study of AAVB-039 in Participants With Stargardt Disease (STGD1) | Biotech Hunter | Biotech Hunter